Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ABT-493/ABT-530 for efficacy and safety in adults with chronic hepatitis C virus infection (genotypes 1, 2, 4, 5, or 6) and compensated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Compensated Cirrhosis
• Hepatitis C

Drugs mentioned

• ABT-493/ABT-530 (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus Infection, Chronic Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2017-09-26